Cargando…
Review of Automated Insulin Delivery Systems for Type 1 Diabetes and Associated Time in Range Outcomes
Automated insulin delivery (AID) systems play an important role in the management of type 1 diabetes mellitus (T1DM). These systems include three components: a continuous glucose monitor (CGM), an insulin pump and an algorithm that adjusts the pump based on the CGM sensor glucose readings. They are...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Touch Medical Media
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9354504/ https://www.ncbi.nlm.nih.gov/pubmed/35949359 http://dx.doi.org/10.17925/EE.2022.18.1.27 |
_version_ | 1784763086956134400 |
---|---|
author | Nallicheri, Armaan Mahoney, Katherine M Gutow, Hanna A Bellini, Natalie Isaacs, Diana |
author_facet | Nallicheri, Armaan Mahoney, Katherine M Gutow, Hanna A Bellini, Natalie Isaacs, Diana |
author_sort | Nallicheri, Armaan |
collection | PubMed |
description | Automated insulin delivery (AID) systems play an important role in the management of type 1 diabetes mellitus (T1DM). These systems include three components: a continuous glucose monitor (CGM), an insulin pump and an algorithm that adjusts the pump based on the CGM sensor glucose readings. They are not fully automated and still require the user to administer bolus insulin doses for food. Some AID systems have automatic correction boluses, while others only have automatic basal or background insulin adjustments. As CGM has become more accurate and the technology has evolved, AID systems have demonstrated improved glycaemic outcomes. The clinical evaluation of AID systems in randomized controlled trials and real-world studies have shown their utility in helping glycaemic management. In this review, we compare AID systems that are commercially available in the US and summarize the literature, with a special focus on time in range in T1DM. The review also discusses new AID systems on the horizon and explores considerations for personalized care. |
format | Online Article Text |
id | pubmed-9354504 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Touch Medical Media |
record_format | MEDLINE/PubMed |
spelling | pubmed-93545042022-08-09 Review of Automated Insulin Delivery Systems for Type 1 Diabetes and Associated Time in Range Outcomes Nallicheri, Armaan Mahoney, Katherine M Gutow, Hanna A Bellini, Natalie Isaacs, Diana touchREV Endocrinol Diabetes Automated insulin delivery (AID) systems play an important role in the management of type 1 diabetes mellitus (T1DM). These systems include three components: a continuous glucose monitor (CGM), an insulin pump and an algorithm that adjusts the pump based on the CGM sensor glucose readings. They are not fully automated and still require the user to administer bolus insulin doses for food. Some AID systems have automatic correction boluses, while others only have automatic basal or background insulin adjustments. As CGM has become more accurate and the technology has evolved, AID systems have demonstrated improved glycaemic outcomes. The clinical evaluation of AID systems in randomized controlled trials and real-world studies have shown their utility in helping glycaemic management. In this review, we compare AID systems that are commercially available in the US and summarize the literature, with a special focus on time in range in T1DM. The review also discusses new AID systems on the horizon and explores considerations for personalized care. Touch Medical Media 2022-06 2022-05-20 /pmc/articles/PMC9354504/ /pubmed/35949359 http://dx.doi.org/10.17925/EE.2022.18.1.27 Text en © Touch Medical Media 2022 ali:free_to_read www.copyright.com (http://www.copyright.com) Review Process: Double-blind peer review. Compliance with ethics: This study involves a review of the literature and did not involve any studies with human or animal subjects performed by any of the authors. Data availability: Data sharing is not applicable to this article as no datasets were generated or analysed during the writing of this study. Authorship: The named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship of this manuscript, take responsibility for the integrity of the work as a whole, and have given final approval for the version to be published. https://creativecommons.org/licenses/by/3.0/Access: This article is freely accessible at touchCARDIO.com (http://touchCARDIO.com) © Touch Medical Media 2022. |
spellingShingle | Diabetes Nallicheri, Armaan Mahoney, Katherine M Gutow, Hanna A Bellini, Natalie Isaacs, Diana Review of Automated Insulin Delivery Systems for Type 1 Diabetes and Associated Time in Range Outcomes |
title | Review of Automated Insulin Delivery Systems for Type 1 Diabetes and Associated Time in Range Outcomes |
title_full | Review of Automated Insulin Delivery Systems for Type 1 Diabetes and Associated Time in Range Outcomes |
title_fullStr | Review of Automated Insulin Delivery Systems for Type 1 Diabetes and Associated Time in Range Outcomes |
title_full_unstemmed | Review of Automated Insulin Delivery Systems for Type 1 Diabetes and Associated Time in Range Outcomes |
title_short | Review of Automated Insulin Delivery Systems for Type 1 Diabetes and Associated Time in Range Outcomes |
title_sort | review of automated insulin delivery systems for type 1 diabetes and associated time in range outcomes |
topic | Diabetes |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9354504/ https://www.ncbi.nlm.nih.gov/pubmed/35949359 http://dx.doi.org/10.17925/EE.2022.18.1.27 |
work_keys_str_mv | AT nallicheriarmaan reviewofautomatedinsulindeliverysystemsfortype1diabetesandassociatedtimeinrangeoutcomes AT mahoneykatherinem reviewofautomatedinsulindeliverysystemsfortype1diabetesandassociatedtimeinrangeoutcomes AT gutowhannaa reviewofautomatedinsulindeliverysystemsfortype1diabetesandassociatedtimeinrangeoutcomes AT bellininatalie reviewofautomatedinsulindeliverysystemsfortype1diabetesandassociatedtimeinrangeoutcomes AT isaacsdiana reviewofautomatedinsulindeliverysystemsfortype1diabetesandassociatedtimeinrangeoutcomes |